About Twist Bioscience
Twist Bioscience is a company based in San Francisco (United States) founded in 2013 by Emily Leproust. Twist Bioscience has raised $245.81 million across 10 funding rounds from investors including Fidelity Investments, Illumina and SVB. The company has 923 employees as of September 30, 2024. Twist Bioscience has completed 3 acquisitions, including Abveris, Genome Compiler Corporation and iGenomX. Twist Bioscience operates in a competitive market with competitors including Amyris, Syngenta, AskBio, Ginkgo Bioworks and Antheia, among others.
- Headquarter San Francisco, United States
- Employees 923 as on 30 Sep, 2024
- Founders Emily Leproust
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Twist Bioscience Corporation
-
Annual Revenue
$376.57 M (USD)20.32as on Sep 30, 2025
-
Net Profit
-$77.67 M (USD)62.79as on Sep 30, 2025
-
EBITDA
-$111.41 M (USD)22.89as on Sep 30, 2025
-
Total Equity Funding
$245.81 M (USD)
in 10 rounds
-
Latest Funding Round
$50 M (USD), Series F
Apr 02, 2018
-
Investors
Fidelity Investments
& 20 more
-
Employee Count
923
as on Sep 30, 2024
-
Investments & Acquisitions
Abveris
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Twist Bioscience
Twist Bioscience is a publicly listed company on the NASDAQ with ticker symbol TWST in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Twist Bioscience
Unlock access to complete
Unlock access to complete
Software Development Team
76 people
Senior Team
45 people
Sales and Marketing
33 people
Product Management Team
22 people
Leadership Team
21 people
Staff Team
8 people
Research Team
7 people
Data Analysis and Operations Team
7 people
Unlock access to complete
Funding Insights of Twist Bioscience
Twist Bioscience has successfully raised a total of $245.81M across 10 strategic funding rounds. The most recent funding activity was a Series F round of $50 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Twist Bioscience
Twist Bioscience has secured backing from 21 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Fidelity Investments, Illumina and SVB.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage tech and life sciences focused VC firm investing primarily in the US
|
Locked | Locked | Locked | |
|
Private equity investments are managed across multiple sectors.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Twist Bioscience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Twist Bioscience
Twist Bioscience has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Abveris, Genome Compiler Corporation and iGenomX.
Investment portfolio details for Twist Bioscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Monoclonal antibodies are discovered rapidly using transgenic rodents.
|
Locked | Locked | 2014 | Locked | |
|
NGS library construction solutions are provided to enhance DNA sequencing.
|
Locked | Locked | 2012 | Locked | |
|
DNA design, visualization, data management, and collaboration tools are provided.
|
Locked | Locked | 2011 | Locked |
Complete acquisition details for Twist Bioscience
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Twist Bioscience
Detailed financials for Twist Bioscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Twist Bioscience Comparisons
Peer comparison for Twist Bioscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Twist Bioscience
Twist Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Syngenta, AskBio, Ginkgo Bioworks and Antheia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Crop protection solutions and hybrid seeds are provided for farming.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Gene editing-based cultured ingredients are provided for agriculture.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
Detailed competitors of Twist Bioscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Twist Bioscience
Complete news archive for Twist Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Twist Bioscience
Twist Bioscience was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Twist Bioscience is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Emily Leproust is the current CEO of Twist Bioscience. They have also founded this company.
Twist Bioscience is a funded company, having raised a total of $245.81M across 10 funding rounds to date.
As of Sep 30, 2024, the latest employee count at Twist Bioscience is 923.
Annual revenue of Twist Bioscience is $376.57M as on Sep 30, 2025.
Twist Bioscience was founded in 2013 in San Francisco, United States, within the biotechnology sector. A proprietary silicon-based manufacturing process is employed for producing synthetic DNA, applicable in medicine, agriculture, industrial chemicals, and data storage. Synthetic genes, oligo pools, and NGS target enrichment services are provided to facilitate research and development efforts across these fields.
Twist Bioscience's top competitors include Syngenta, Synthego and Nuclera Nucleics.
Yes, Twist Bioscience is publicly traded on NASDAQ under the ticker symbol TWST.
Twist Bioscience has made 3 acquisitions, including Abveris, Genome Compiler Corporation, and iGenomX.
Twist Bioscience has 21 investors. Key investors include Fidelity Investments, Illumina, SVB, Applied Materials, and FIS.
The ticker symbol of Twist Bioscience is TWST on NASDAQ.